Abstract
Cytochrome P450 (CYP) mono-oxygenases represent one of the major enzyme systems that determine the organism’s capability of dealing with drugs and chemicals. Studies over the past 20 years have provided evidence that cytochromes P450 occur in many different forms (isoforms or isozymes) which differ in spectral, chemical, and immunological properties and have different substrate affinities. These isozymes also differ in their regulation and tissue distribution. Recombinant DNA studies indicate that between 50 and 200 structural genes may code for different cytochrome P450 isozymes in a single organism. Close to 30 human cytochrome P450 genes have now been characterized. The multiplicity of P450 isozymes explains in part the literally thousands of substrates known to be metabolized by this system (for review, see Nelson et al. 1993).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521–530
Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA (1989) Lidocaine metabolism in human liver by cytochrome P450IIIA4 (PCN1). Clin Pharmacol Ther 46: 521–527
Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545–558
Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther 57: 129–160
DeMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for thepolymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15422–15422
Fonné-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3835
Gascon MP, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573–578
Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYPC19 is the major s-mephenytoin 4’hydroxylase in humans. Biochemistry (in press)
Gonzalez FJ (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13: 346–352
Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: 287–295
Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529–532
Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoeqvist F, IngelmanSundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90: 11825–11829
Kalow W (1992) Pharmacogenetics of drug metabolism international encyclopedia of pharmacology and therapeutics (executive editor AC Sartorelli). Pergamon, London
Kalow W, Goedde HW, Agarwal DP (1986) Ethnic differences in reactions to drugs and xenobiotics. Liss, New York
Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635
Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89–96
Meier PJ, Mueller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85: 682–692
Meyer UA (1994) Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91 (in press)
Meyer UA, Zanger UM, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. In: Testa B (ed) Advances in drug research, vol 19. Academic, London, pp 307–23
Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993) the P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12: 1–51
Okey AB (1990) Enzyme induction in the cytochrome P450 system. Pharmacol Ther 45: 241–298
Waxman DJ, Azaroff L (1992) Phenobarbital induction of cytochrome P450 gene expression. Biochem J 281: 577–592
Whitlock JP (1993) Mechanistic aspects of dioxin action. Chem Res Toxicol 6: 754–763
Wilkinson GR, Guengerich FP, Branch RA (1992) Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed) Pharmacogenetics of drug metabolism, vol 2. Pergamon, New York, 657–685
Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Meyer, U.A. (1994). Cytochrome P450 in Human Drug Metabolism: How Much Is Predictable?. In: Waterman, M.R., Hildebrand, M. (eds) Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research. Ernst Schering Research Foundation Workshop, vol 13. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03019-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-03019-6_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-03021-9
Online ISBN: 978-3-662-03019-6
eBook Packages: Springer Book Archive